167 related articles for article (PubMed ID: 35396971)
1. Saponin-based adjuvant-induced dendritic cell cross-presentation is dependent on PERK activation.
Huis In 't Veld LGM; Ho NI; Wassink M; den Brok MH; Adema GJ
Cell Mol Life Sci; 2022 Apr; 79(5):231. PubMed ID: 35396971
[TBL] [Abstract][Full Text] [Related]
2. Saponin-based adjuvants enhance antigen cross-presentation in human CD11c
Ho NI; Huis In 't Veld LGM; van Eck van der Sluijs J; Heuts BMH; Looman MWG; Kers-Rebel ED; van den Dries K; Dolstra H; Martens JHA; Hobo W; Adema GJ
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37612044
[TBL] [Abstract][Full Text] [Related]
3. Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation.
den Brok MH; Büll C; Wassink M; de Graaf AM; Wagenaars JA; Minderman M; Thakur M; Amigorena S; Rijke EO; Schrier CC; Adema GJ
Nat Commun; 2016 Nov; 7():13324. PubMed ID: 27819292
[TBL] [Abstract][Full Text] [Related]
4. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
[TBL] [Abstract][Full Text] [Related]
5. Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?
Ho NI; Huis In 't Veld LGM; Raaijmakers TK; Adema GJ
Front Immunol; 2018; 9():2874. PubMed ID: 30619259
[TBL] [Abstract][Full Text] [Related]
6. Carbomer-based adjuvant elicits CD8 T-cell immunity by inducing a distinct metabolic state in cross-presenting dendritic cells.
Lee W; Kingstad-Bakke B; Paulson B; Larsen A; Overmyer K; Marinaik CB; Dulli K; Toy R; Vogel G; Mueller KP; Tweed K; Walsh AJ; Russell J; Saha K; Reyes L; Skala MC; Sauer JD; Shayakhmetov DM; Coon J; Roy K; Suresh M
PLoS Pathog; 2021 Jan; 17(1):e1009168. PubMed ID: 33444400
[TBL] [Abstract][Full Text] [Related]
7. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
[TBL] [Abstract][Full Text] [Related]
8. A marked reduction in priming of cytotoxic CD8+ T cells mediated by stress-induced glucocorticoids involves multiple deficiencies in cross-presentation by dendritic cells.
Hunzeker JT; Elftman MD; Mellinger JC; Princiotta MF; Bonneau RH; Truckenmiller ME; Norbury CC
J Immunol; 2011 Jan; 186(1):183-94. PubMed ID: 21098225
[TBL] [Abstract][Full Text] [Related]
9. Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes.
Raaijmakers TK; van den Bijgaart RJE; den Brok MH; Wassink M; de Graaf A; Wagenaars JA; Nierkens S; Ansems M; Scheffer GJ; Adema GJ
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461350
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel antigen cross-presenting cell type in spleen.
Tan JK; Quah BJ; Griffiths KL; Periasamy P; Hey YY; O'Neill HC
J Cell Mol Med; 2011 May; 15(5):1189-99. PubMed ID: 20477902
[TBL] [Abstract][Full Text] [Related]
11. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
12. Cross-Priming Dendritic Cells Exacerbate Immunopathology After Ischemic Tissue Damage in the Heart.
Forte E; Perkins B; Sintou A; Kalkat HS; Papanikolaou A; Jenkins C; Alsubaie M; Chowdhury RA; Duffy TM; Skelly DA; Branca J; Bellahcene M; Schneider MD; Harding SE; Furtado MB; Ng FS; Hasham MG; Rosenthal N; Sattler S
Circulation; 2021 Feb; 143(8):821-836. PubMed ID: 33297741
[TBL] [Abstract][Full Text] [Related]
13. A role for lipid bodies in the cross-presentation of phagocytosed antigens by MHC class I in dendritic cells.
Bougnères L; Helft J; Tiwari S; Vargas P; Chang BH; Chan L; Campisi L; Lauvau G; Hugues S; Kumar P; Kamphorst AO; Dumenil AM; Nussenzweig M; MacMicking JD; Amigorena S; Guermonprez P
Immunity; 2009 Aug; 31(2):232-44. PubMed ID: 19699172
[TBL] [Abstract][Full Text] [Related]
14. Stroma-dependent development of two dendritic-like cell types with distinct antigen presenting capability.
Periasamy P; O'Neill HC
Exp Hematol; 2013 Mar; 41(3):281-92. PubMed ID: 23178375
[TBL] [Abstract][Full Text] [Related]
15. Effective Priming of Herpes Simplex Virus-Specific CD8
Whitney PG; Makhlouf C; MacLeod B; Ma JZ; Gressier E; Greyer M; Hochheiser K; Bachem A; Zaid A; Voehringer D; Heath WR; Wagle MV; Parish I; Russell TA; Smith SA; Tscharke DC; Gebhardt T; Bedoui S
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142130
[TBL] [Abstract][Full Text] [Related]
16. Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction.
den Brok MH; Nierkens S; Wagenaars JA; Ruers TJ; Schrier CC; Rijke EO; Adema GJ
Vaccine; 2012 Jan; 30(4):737-44. PubMed ID: 22138178
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading.
Robson NC; Beacock-Sharp H; Donachie AM; Mowat AM
Immunology; 2003 Jul; 109(3):374-83. PubMed ID: 12807483
[TBL] [Abstract][Full Text] [Related]
18. A Vaccination with Boosted Cross Presentation by ER-Targeted Antigen Delivery for Anti-Tumor Immunotherapy.
Shi Y; Zhu C; Liu Y; Lu Y; Li X; Qin B; Luo Z; Luo L; Jiang M; Zhang J; Guan G; Zheng C; You J
Adv Healthc Mater; 2021 Apr; 10(8):e2001934. PubMed ID: 33502831
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
Didierlaurent AM; Collignon C; Bourguignon P; Wouters S; Fierens K; Fochesato M; Dendouga N; Langlet C; Malissen B; Lambrecht BN; Garçon N; Van Mechelen M; Morel S
J Immunol; 2014 Aug; 193(4):1920-30. PubMed ID: 25024381
[TBL] [Abstract][Full Text] [Related]
20. Sustained cross-presentation capacity of murine splenic dendritic cell subsets in vivo.
Ho NI; Camps MGM; de Haas EFE; Ossendorp F
Eur J Immunol; 2018 Jul; 48(7):1164-1173. PubMed ID: 29676785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
